Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Engineering the immune response in Parkinson’s disease to curb its pathological progression

Project description

Targeted immunotherapy for Parkinson’s disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused by the accumulation of alpha synuclein, a protein that regulates synaptic vesicle trafficking and neurotransmitter release. Abnormal forms of alpha synuclein activate immune cells in the brain, causing neuroinflammation and accelerating neurodegeneration. The ERC-funded CARgiver project aims to develop a novel targeted therapy using chimeric antigen receptor (CAR) regulatory T cells (Tregs) that suppress immune activation only where pathological alpha synuclein is present. Researchers will test the efficacy of these CAR Tregs in mouse and humanised PD models. Additionally, they will engineer CAR Tregs to locally prevent alpha synuclein aggregation, offering a disease-modifying treatment that may be applied across all PD stages.

Objective

Mounting evidence has defined the key role played by the immune system in exacerbating dopaminergic neuron loss in Parkinson’s disease (PD). Pathological alpha-Synuclein (αSYN) activates microglia and recruits inflamed T cells, creating a toxic environment that directly negatively impact on neurodegenerative processes. Blocking or attenuating neuroinflammation can have a strong therapeutic potential in PD, but systemic treatments are associated with immune system general suppression leading to severe and unacceptable side effects. Therefore, a therapeutic strategy for long-term and local immune suppression would minimize adverse effects and provide a long-sought disease-modifying treatment for PD. To achieve this goal, we have generated αSYN-specific CAR T regulatory cells (Tregs) that are activated and recruited only in the presence of toxic αSYN aggregates, suppressing immune activation. Herein, we will determine the therapeutic efficacy of mouse and human αSYN-CAR Tregs in conventional and humanized mice with virally-induced synucleinopathy. These experiments will determine the dose and infusion schedule that will achieve maximal neuroprotection and symptomatic rescue with none or minimal side effects. Moreover, innovative all-human neuroimmune organoids will be generated by assembling patient and isogenic iPSC-derived neural, astroglial and microglial cells together with freshly isolated T cells and αSYN-CAR Tregs. This model will recapitulate human-specific neuroinflammatory processes and validate the capacity of αSYN-CAR Tregs to interfere with them. Finally, we conceived αSYN-CAR Tregs as ideal cellular shuttles for the local delivery of therapeutic molecules and this concept will be explore to express αSYN anti-aggregating agents. This treatment is of potential benefit for the entire PD patient population at any given stage of the disease and pharmacological regimen, and with a straightforward clinical implementation path using an autologous cellular source.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-ADG

See all projects funded under this call

Host institution

CONSIGLIO NAZIONALE DELLE RICERCHE
Net EU contribution
€ 2 493 000,00
Address
PIAZZALE ALDO MORO 7
00185 Roma
Italy
Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)